Skip to Main Content

INFORMATION FOR

Michal Rose, MD

Professor; Director, VA Comprehensive Cancer Center

Contact Information

Michal Rose, MD

Mailing Address

  • Medical Oncology

    VA Connecticut Healthcare System, 950 Campbell Avenue (III-d)

    West Haven, CT 06516

    United States

Research Summary

I am interested in the interface between oncology/hematology and primary care and improving timeliness and efficiency of oncology and hematology care.

Research Interests

Health Services Research; Hematology; Medical Oncology; Veterans

Public Health Interests

Health Care Management

Selected Publications

  • Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.Xiang J, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Perry L, Connery D, Rose M, Chao H. Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience. Journal Of Clinical Oncology 2021, 39: 79-79. DOI: 10.1200/jco.2020.39.28_suppl.79.
  • "Lost to Follow-Up?" Barriers to Lung Cancer Screening Adherence in US VeteransBade B, DeRycke E, Kunitomo Y, Lerz K, Skanderson M, Rose M, DiDomenico P, Conti M, Taylor C, Crothers K, Federman D, Haskell S, Bean-Mayberry B, Brandt C, Bastian L, Akgun K, Cain H. "Lost to Follow-Up?" Barriers to Lung Cancer Screening Adherence in US Veterans 2021, a4775-a4775. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4775.
  • Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer.Presley C, Kaur K, Han L, Soulos P, Zhu W, Corneau E, O'Leary J, Chao H, Shamas T, Rose M, Lorenz K, Levy C, Mor V, Gross C. Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer. Journal Of Clinical Oncology 2020, 38: 12025-12025. DOI: 10.1200/jco.2020.38.15_suppl.12025.
  • Comorbidities in Veterans Undergoing Lung Cancer ScreeningBade B, DeRycke E, Lerz K, Skanderson M, Rose M, Obando A, Taylor C, Crothers K, Haskell S, Bean-Mayberry B, Brandt C, Bastian L, Akgun K, Cain H. Comorbidities in Veterans Undergoing Lung Cancer Screening 2020, a5924-a5924. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5924.
  • Multicenter phase II trial of RRx-001 in previously treated SCLC.Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.
  • Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple MyelomaGiri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma Blood 2018, 132: 3162-3162. DOI: 10.1182/blood-2018-99-115633.
  • QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.
  • Concurrent Care and Aggressive End-of-Life Lung Cancer CarePresley C, Han L, O'leary J, Chao H, Shamas T, Kerin A, Rose M, Gross C. Concurrent Care and Aggressive End-of-Life Lung Cancer Care Journal Of Thoracic Oncology 2017, 12: s1545. DOI: 10.1016/j.jtho.2017.06.058.
  • Gleason grade in HIV+ versus uninfected prostate cancer patients in the Veterans Aging Cohort study.Wadia R, Park L, Brandt C, Rose M, Chao H, Gibert C, Rimland D, Rodriguez-Barradas M, Justice A. Gleason grade in HIV+ versus uninfected prostate cancer patients in the Veterans Aging Cohort study. Journal Of Clinical Oncology 2016, 34: e16560-e16560. DOI: 10.1200/jco.2016.34.15_suppl.e16560.
  • Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient SatisfactionNeparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction Blood 2014, 124: 4857-4857. DOI: 10.1182/blood.v124.21.4857.4857.
  • Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS).Wadia R, Yao X, Deng Y, Li J, Maron S, Connery D, Gunduz-Bruce H, Rose M. Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS). Journal Of Clinical Oncology 2014, 32: 6542-6542. DOI: 10.1200/jco.2014.32.15_suppl.6542.
  • EMR-linked cancer tracker facilitates lung and liver cancer care.Taddei T, Hunnibell L, DeLorenzo A, Rosa M, Connery D, Vogel D, Garla V, Taylor C, Rose M. EMR-linked cancer tracker facilitates lung and liver cancer care. Journal Of Clinical Oncology 2012, 30: 77-77. DOI: 10.1200/jco.2012.30.34_suppl.77.
  • Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center.Alsamarai S, Chao H, Yao X, Deng Y, Rose M. Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center. Journal Of Clinical Oncology 2012, 30: 6033-6033. DOI: 10.1200/jco.2012.30.15_suppl.6033.
  • Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study.Munshi N, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera Y, Houranieh A, Brophy M, Zimelman A, Prabhala R, Grady T, Klein C, Mehta P, Hayes T, Roodman G, Lichtenstein A. Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. Journal Of Clinical Oncology 2011, 29: 8074-8074. DOI: 10.1200/jco.2011.29.15_suppl.8074.
  • Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of TherapyChao H, Mayer T, Concato J, Rose M, Uchio E, Kelly K. Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy Journal Of Investigative Medicine 2010, 58: 566. DOI: 10.2310/jim.0b013e3181cf9002.
  • Chapter 49 Disorders of Red Blood CellsRose M, Berliner N. Chapter 49 Disorders of Red Blood Cells 2010, 520-532. DOI: 10.1016/b978-1-4160-6109-0.00049-6.
  • Chapter 50 Clinical Disorders of NeutrophilsRose M, Berliner N. Chapter 50 Clinical Disorders of Neutrophils 2010, 533-538. DOI: 10.1016/b978-1-4160-6109-0.00050-2.
  • Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)Galper S, Deshpande H, Rose M, Decker R. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC) Journal Of Clinical Oncology 2009, 27: e17030-e17030. DOI: 10.1200/jco.2009.27.15_suppl.e17030.